PIK3CA mutation in Chinese patients with lung squamous cell carcinoma

Chinese Journal of Cancer Research

Volumn 25, Issue 4, 2013, Pages 416-422

  Yu, Jinglin ^a   Bai, Hua ^a   Wang, Zhijie ^a   Wei, Zhigang ^a   Ding, Xiaosheng ^a   Duan, Jianchun ^a   Yang, Lu ^a   Wu, Meina ^a   Wang, Yuyan ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

EGFR mutation; KRAS mutation; Lung squamous cell carcinoma (LSCC); PIK3CA mutation

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; CANCER STAGING; CHINESE; CLONE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PYROSEQUENCING; SEX DIFFERENCE; SMOKING; WILD TYPE;

EID: 84883758401     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2013.08.03     Document Type: Article

References (31)

1. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31.
2. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4. (Pubitemid 34743088)
3. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62. (Pubitemid 34008191)
4. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
6. McLeer-Florin A, Lantuéjoul S. Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. J Thorac Dis 2012;4:240-1.
7. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893-7.
8. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutation on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer cell 2006;9:485-95. (Pubitemid 43832191)
9. Manning BD, Cantley LC. AKT/PKB signalling: navigating downstream. Cell 2007;129:1261-74.
10. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/ Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204. (Pubitemid 38418057)
11. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
12. Volinia S, Hiles I, Ormondoryd E, et al. Molecular cloning, cDNA sequence, and chromosomal locolization of the human phosphatidylinositol 3-klnase p110 alpha (PlK3CA) gene. Genomics 1994;24:472-7.
13. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-9. (Pubitemid 43289745)
14. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82. (Pubitemid 43740454)
15. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73. (Pubitemid 40799249)
16. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non- small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
17. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010:237-46.
18. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-3.
19. Daniels M, Goh F, Wright CM, et al. Whole genome sequencing for lung cancer. J Thorac Dis 2012;4:155-63.
20. Eberhard DA, Johnson BE, Amler LC, et al. Mutation in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicator in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Cli Oncol 2005;23:5900-9.
21. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-8.
22. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-7. (Pubitemid 350232256)
23. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5. (Pubitemid 41351083)
24. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81. (Pubitemid 39446895)
25. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80. (Pubitemid 40343128)
26. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54:209-15. (Pubitemid 44764916)
27. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-71. (Pubitemid 47353042)
28. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
29. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-7. (Pubitemid 40282746)
30. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7. (Pubitemid 40740791)
31. Endoh H, Yatabe Y, Kosaka T, et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006;1:629-34. (Pubitemid 47163949)